{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
vitamin a palmitate
to a specific field?
Status:
Investigational
Source:
NCT02864888: Phase 3 Interventional Not yet recruiting Brain Stem Glioma
(2027)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Antineoplaston A10 is a piperidinedione antineoplaston with potential antineoplastic activity. Antineoplaston A10 was originally isolated from human urine but is now synthetically derived. This agent intercalates into DNA, resulting in cell cycle arrest in G1 phase, reduction of mitosis, and decreased protein synthesis. Antineoplaston A10 may also inhibit ras-oncogene expression and activate tumor suppressor gene p53, leading to cell differentiation and apoptosis. Antineoplaston A10 has been used in trials studying the treatment of glioma, sarcoma, lymphoma, lung cancer, liver cancer, and kidney cancer, among others.
Status:
Investigational
Source:
NCT00219609: Phase 2/Phase 3 Interventional Completed Ejaculation
(2005)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
UK-390957 is a selective serotonin reuptake inhibitor (SSRI) that was in phase II/III development in the USA, European Union and other territories with Pfizer, for the treatment of Premature ejaculation. UK-390957 represented a major development in sexual medicine, and offered patients the convenience of on-demand dosing, significant improvements in IELT, ejaculatory control, and sexual satisfaction with minimal adverse effects. However development of UK-390957 was discontinued.
Status:
Investigational
Source:
NCT01039844: Phase 1 Interventional Terminated Melanoma
(2009)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Class (Stereo):
CHEMICAL (ABSOLUTE)
KETAZOCINE, a benzomorphan derivative, is a kappa opioid receptor agonist. It is used in opioid receptor research.
Status:
Investigational
Source:
NCT01561456: Phase 2 Interventional Completed Non-small-cell Lung Cancer
(2011)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Picropodophyllin (also known as picropodophyllotoxin (PPP)), an orally active insulin-like growth factor 1 receptor (IGF1R) inhibitor that exhibits no activity at the insulin receptor, FGFR, PDGFR or EGFR. Picropodophyllin possesses antineoplastic activity. PPP is currently tested as an orally administrated single agent treatment in an open-label combined Phase I/II clinical study in advanced cancer patients with solid tumors which progress in spite of several lines of treatment. In addition, it effectively inhibits rhambodmyosarcomas tumor proliferation and metastasis in vitro and in an animal model.
Status:
Investigational
Source:
NCT00003328: Phase 3 Interventional Completed Head and Neck Cancer
(1997)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Porfiromycin is an N-methyl derivative of the antineoplastic antibiotic mitomycin-C initially isolated from Streptomyces ardus. Upon administration, the drug undergoes chemical or enzymatic reduction, followed by spontaneous loss of the tertiary methoxy (hydroxyl) group and formation of an aromatic indole system. Thus activated, porfiromycin generates oxygen radicals and alkylates DNA, producing interstrand cross-links and single-strand breaks at guanosine residues. Porfiromycin was tested in phase III for head and neck carcinoma, however, its development was terminated.
Status:
Investigational
Source:
Diabetes Obes Metab. Mar 2023;25(3):832-843.: Phase 2 Human clinical trial Completed Diabetes Mellitus, Type 2/complications
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Status:
Investigational
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
Chloralose (alpha-Chloralose, 1,2-O-(2,2,2-Trichloroethylidene)-α-D-glucofuranose) is an avicide, and a rodenticide commonly used for the control of mice and birds. Since its initial description in 1893, alpha-chloralose has undergone extensive pharmacologic evaluation. It has been characterized as a compound possessing potent CNS activity and has been evaluated in humans and animal models for its therapeutic properties. Though the toxicity of the compound prohibits its use as a human therapeutic agent, it has been employed widely as an animal anesthetic in the laboratory setting. α-Chloralose is widely used as an anesthetic in studies of the cerebrovasculature because of its presumed minimal depression of autonomic function. α-Chloralose acts as the positive allosteric modulator of GABA-A receptor and increases the affinity for GABA 5-fold and produced a small increase in the efficacy of GABA. Studies of α-Chloralose interactions with other allosteric modulators determined that α-Chloralose binds to a site on the GABAA receptor complex distinct from the benzodiazepine, neurosteroid and barbiturate sites.
Status:
Investigational
Source:
NCT00454103: Phase 1/Phase 2 Interventional Completed Adrenal Tumor
(2007)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Iodometomidate I-123, R- (also known as ) is phenylethylimidazole derivative studied as a diagnostic agent for adrenal imaging. Iodometomidate is a highly suitable tracer combining specific uptake in adrenocortical tissue with far lower radiation exposure compared to norcholesterol scintigraphy. Phase III clinical trial for Adrenal Gland Neoplasms imaging is currently ongoing.
Class (Stereo):
CHEMICAL (ACHIRAL)
Sulfacecole is an isoxazolylsulfanilamide derivative patented by Hoffmann -La Roche, F., und Co., A.-G. as antibacterial agent.